Buspirone
buspirone hydrochloride — formerly marketed as BuSpar
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Generalized anxiety disorder (GAD) | Adults | Monotherapy | FDA Approved |
| Short-term relief of anxiety symptoms | Adults | Monotherapy | FDA Approved |
Buspirone is approved for the management of anxiety disorders and the short-term relief of anxiety symptoms in adults. Its efficacy has been established in controlled trials of outpatients whose presentations correspond to generalized anxiety disorder, including patients with coexisting depressive symptoms. Buspirone is not approved for pediatric use — two placebo-controlled trials in children aged 6–17 years failed to demonstrate separation from placebo. Long-term efficacy beyond 3–4 weeks has not been established in controlled trials, though an open-label study treated 264 patients for one year without notable safety concerns.
SSRI/SNRI augmentation for major depressive disorder — The STAR*D trial (Level 2) evaluated buspirone augmentation of citalopram and showed modest benefit. Evidence quality: Moderate.
SSRI-induced sexual dysfunction — Small studies suggest buspirone 15–60 mg/day may attenuate SSRI-associated sexual side effects via 5-HT1A agonism. Evidence quality: Low.
Tardive dyskinesia — Open-label data suggest high-dose buspirone (up to 180 mg/day) may reduce abnormal involuntary movements. Evidence quality: Low.
Social anxiety disorder / PTSD — Limited evidence from small trials; not widely adopted. Evidence quality: Very low.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| GAD — initial monotherapy | 7.5 mg BID | 15–30 mg/day in divided doses | 60 mg/day | Increase by 5 mg/day q2–3 days as tolerated Onset of effect: 1–2 weeks; full response may take 4–6 weeks |
| GAD — switching from a benzodiazepine | 5 mg BID–TID | 15–30 mg/day | 60 mg/day | Taper benzodiazepine gradually before or during initiation Buspirone does NOT cover benzodiazepine withdrawal |
| Anxiety with comorbid depression — SSRI augmentation | 5 mg BID | 15–30 mg/day | 60 mg/day | Monitor for serotonergic effects when combined with SSRIs Off-label; supported by STAR*D data |
| Use with potent CYP3A4 inhibitors | 2.5 mg BID or 2.5 mg daily | Titrate cautiously | Individualize | Required when co-prescribing itraconazole, nefazodone, erythromycin, or strong CYP3A4 inhibitors Itraconazole increases buspirone AUC 19-fold (FDA PI) |
| Use with potent CYP3A4 inducers | Standard starting dose | May need dose increase | 60 mg/day | Rifampin reduces buspirone AUC by ~90%; dose adjustment needed Other inducers: phenytoin, carbamazepine, phenobarbital |
Special Population Adjustments
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Elderly (≥65 years) | 5 mg BID | 15–30 mg/day | 60 mg/day | No pharmacokinetic differences observed by age; start low as a precaution |
| Renal impairment (CrCl 10–70 mL/min) | Use with caution — AUC increased ~4-fold | Reduce dose empirically; not recommended in severe impairment | ||
| Hepatic impairment | Use with caution — AUC increased ~13-fold | Not recommended in severe hepatic disease (FDA PI) | ||
Food increases buspirone AUC by 84% and Cmax by 116% by reducing first-pass metabolism. Patients should take buspirone consistently — always with food or always without — to avoid erratic plasma levels and unpredictable symptom control.
Pharmacology
Mechanism of Action
Buspirone is an azapirone anxiolytic that acts primarily as a partial agonist at serotonin 5-HT1A receptors, both presynaptic (somatodendritic autoreceptors in the raphe nuclei) and postsynaptic (in the hippocampus and cortex). At presynaptic sites, partial agonism initially reduces serotonergic firing; with chronic administration, autoreceptors desensitize and serotonin neurotransmission is gradually restored — a timeline that mirrors the 1–2 week delay before clinical anxiolysis becomes apparent. Buspirone also exhibits moderate affinity for dopamine D2 receptors, where it appears to act as an antagonist at postsynaptic sites and a partial agonist at presynaptic autoreceptors. It has no clinically significant activity at GABAA-benzodiazepine receptors, which explains the absence of anticonvulsant, muscle-relaxant, and withdrawal properties that characterize benzodiazepines.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed; Tmax 40–90 min; absolute bioavailability ~4% (highly variable due to extensive first-pass); food increases AUC 84% | Counsel patients to take with or without food consistently; variable plasma levels between patients are expected |
| Distribution | Protein binding ~86%; plasma levels 1–6 ng/mL after single 20 mg dose | Does not displace highly protein-bound drugs (phenytoin, warfarin, propranolol); may displace digoxin |
| Metabolism | Hepatic oxidation via CYP3A4; active metabolite 1-pyrimidinylpiperazine (1-PP) with ~25% activity of parent; nonlinear pharmacokinetics at higher doses | Highly sensitive CYP3A4 substrate — strong inhibitors dramatically increase exposure (up to 19-fold with itraconazole); dose adjustment mandatory |
| Elimination | t½ 2–3 h; 29–63% urinary (as metabolites) within 24 h; 18–38% fecal | Short half-life necessitates BID–TID dosing; AUC increases 4-fold in renal impairment and 13-fold in hepatic impairment |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 12% (vs 3% placebo) | Most commonly reported effect; typically transient and dose-related; may limit titration speed |
| Drowsiness | 10% (vs 9% placebo) | Notably less sedating than benzodiazepines; marginal difference versus placebo suggests only modest contribution from the drug itself |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 8% (vs 5% placebo) | Often mitigated by taking with food consistently; tends to improve within the first week |
| Headache | 6% (vs 3% placebo) | Usually mild and self-limiting; evaluate for co-medication contribution if persistent |
| Nervousness | 5% (vs 1% placebo) | Paradoxical in an anxiolytic; distinguish from incomplete treatment response to underlying anxiety |
| Fatigue | 4% (vs 4% placebo) | No difference from placebo; likely not a true drug effect in most patients |
| Insomnia | 3% (vs 3% placebo) | Matches placebo rate; differentiate from pre-existing anxiety-related sleep disturbance |
| Lightheadedness | 3% (vs <1% placebo) | Related to serotonergic and dopaminergic activity; caution when driving |
| Dry mouth | 3% (vs 4% placebo) | Less than placebo rate; likely not a true drug effect |
| Excitement | 2% (vs <1% placebo) | May reflect initial activation; usually self-resolving |
| Decreased concentration | 2% (vs 2% placebo) | Equals placebo rate; less cognitive impairment than benzodiazepines |
| Anger/hostility | 2% (vs <1% placebo) | Uncommon; consider discontinuation if marked behavioral change occurs |
| Confusion | 2% (vs <1% placebo) | More likely in elderly or when combined with other CNS-active agents |
| Depression | 2% (vs 2% placebo) | Matches placebo rate; differentiate emergent depressive symptoms from the underlying anxiety disorder |
| Numbness | 2% (vs <1% placebo) | Paresthesia also reported at 1%; typically transient |
| Blurred vision | 2% (vs <1% placebo) | Mild; evaluate for other causes if persistent |
| Abdominal distress | 2% (vs 2% placebo) | Matches placebo; consider taking with food |
| Diarrhea | 2% (vs <1% placebo) | Usually self-limiting |
| Musculoskeletal aches | 1% (vs <1% placebo) | Non-specific; evaluate if persistent |
| Sweating/clamminess | 1% (vs <1% placebo) | May reflect autonomic serotonergic effects |
| Skin rash | 1% (vs <1% placebo) | Discontinue and evaluate if progresses or accompanied by systemic symptoms |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Serotonin syndrome | Rare | Hours to days after dose change or combination initiation | Discontinue all serotonergic agents immediately; supportive care; cyproheptadine in severe cases; ICU if autonomic instability |
| Angioedema / severe allergic reaction | Very rare | Any time during treatment | Discontinue permanently; emergency treatment; do not rechallenge |
| Dystonic reactions / extrapyramidal symptoms | Very rare (postmarketing reports) | Days to weeks; one reported case at day 28 | Discontinue buspirone; diphenhydramine or benztropine for acute dystonia; do not rechallenge |
| Akathisia / restlessness | Rare | Shortly after initiation | Reduce dose or discontinue; distinguish from anxiety symptoms; propranolol may help if needed |
| Seizures | Very rare (infrequent in premarketing) | Variable | Discontinue; neurological evaluation; buspirone has no anticonvulsant activity |
| Hepatotoxicity (elevated transaminases) | Very rare (case reports with trazodone co-use) | Weeks to months | Check LFTs; discontinue if ALT >3× ULN with symptoms |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| CNS disturbances (dizziness, insomnia, nervousness, drowsiness, lightheadedness) | 3.4% | Most common cluster leading to withdrawal; dose-related effects |
| GI disturbances (primarily nausea) | 1.2% | May be reduced by consistent dosing with food |
| Headache and fatigue | 1.1% | Classified under miscellaneous disturbances |
| Multiple non-specific complaints | 3.4% | No single primary adverse event identified |
Dizziness is the most clinically impactful side effect, affecting about 12% of patients (versus 3% on placebo). It is dose-related and typically improves over the first 1–2 weeks. To minimize impact, start at the lower end of the dosing range (5–7.5 mg BID), increase gradually every 2–3 days, and advise patients to avoid sudden position changes. If dizziness persists beyond 2–3 weeks at a stable dose, consider dose reduction before discontinuation.
Drug Interactions
Buspirone is extensively metabolized by CYP3A4 and is a highly sensitive substrate of this enzyme. Strong CYP3A4 inhibitors can increase buspirone exposure by 5- to 19-fold, while strong inducers can render it essentially ineffective. Buspirone also has serotonergic activity, creating a potential for serotonin syndrome when combined with other serotonin-enhancing agents.
The FDA label advises careful observation when buspirone is used with triptans (5-HT1 agonists) due to theoretical serotonin syndrome risk. When combined with SSRIs/SNRIs for augmentation, serotonin syndrome remains rare but clinicians should counsel patients on the warning signs: agitation, hyperthermia, clonus, hyperreflexia, diaphoresis, and tremor.
Monitoring
Buspirone does not require routine laboratory monitoring under most circumstances. There are no specific laboratory tests recommended in the FDA label. Monitoring focuses primarily on clinical response and tolerability.
-
Anxiety symptom severity
Baseline, 2 wk, 4 wk, then q3 months
Routine Use a validated scale (e.g., GAD-7 or HAM-A). Clinical onset typically 1–2 weeks; reassess efficacy at 4–6 weeks before considering dose change or alternative agent. -
Renal function
Baseline
Routine Obtain baseline creatinine and eGFR. AUC increases approximately 4-fold in renal impairment (CrCl 10–70). Avoid use in severe renal impairment. -
Hepatic function
Baseline
Routine Obtain baseline LFTs. AUC increases approximately 13-fold in hepatic impairment. Avoid use in severe hepatic disease. -
Serotonin syndrome signs
Each visit; heightened vigilance with serotonergic co-medications
Trigger-based Assess for agitation, myoclonus, hyperreflexia, diaphoresis, hyperthermia. Risk is highest when buspirone is combined with SSRIs, SNRIs, triptans, or MAOIs. -
Movement disorders
Each visit
Trigger-based Monitor for akathisia, dystonia, or extrapyramidal symptoms (rare postmarketing reports). Consider discontinuation if movement abnormalities emerge. -
Catecholamine testing interference
Before pheochromocytoma workup
Trigger-based Buspirone may cause false-positive urinary metanephrine results. Discontinue buspirone at least 48 hours before urine collection for catecholamine assay.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to buspirone hydrochloride — anaphylaxis and angioedema have been reported postmarketing.
- Concurrent use of MAOIs (irreversible or reversible, including linezolid and intravenous methylene blue) — risk of serotonin syndrome and hypertensive crisis. A 14-day washout is required after MAOI discontinuation.
Relative Contraindications (Specialist Input Recommended)
- Severe hepatic impairment — buspirone AUC increases 13-fold; not recommended by the FDA label. If essential, use very low doses under hepatology co-management.
- Severe renal impairment — buspirone AUC increases 4-fold; not recommended in severe disease. Nephrology guidance advised.
- Active substance withdrawal (benzodiazepines, alcohol, barbiturates) — buspirone has no GABAergic activity and will not prevent or treat withdrawal seizures. A withdrawal-appropriate taper must be completed first.
Use with Caution
- Concurrent potent CYP3A4 inhibitors or inducers — dose adjustment is mandatory (see Dosing and Drug Interactions sections).
- Elderly patients — no pharmacokinetic differences established by age, but increased sensitivity to CNS-active agents is possible; start with lower doses.
- Patients with history of movement disorders — rare postmarketing reports of dystonia, akathisia, and extrapyramidal symptoms.
- Patients requiring catecholamine testing — buspirone can produce false-positive urinary metanephrine results; discontinue at least 48 hours before testing.
- Driving and operating machinery — buspirone is less impairing than benzodiazepines, but individual responses vary; caution until effect is established.
Buspirone, as a 5-HT1A agonist, has been associated with serotonin syndrome when used alone or in combination with other serotonergic agents (including SSRIs, SNRIs, triptans, and MAOIs). Signs include mental status changes, autonomic instability, neuromuscular abnormalities, and GI symptoms. Serotonin syndrome can be life-threatening. The risk is heightened with concurrent use of agents that impair serotonin metabolism, particularly MAOIs. Clinicians should educate patients on early warning signs and discontinue all serotonergic agents immediately if serotonin syndrome is suspected.
Patient Counselling
Purpose of Therapy
Buspirone is a non-benzodiazepine anxiolytic used to manage generalized anxiety. Unlike benzodiazepines, it does not work immediately — patients should understand that meaningful improvement typically begins at 1–2 weeks, with full therapeutic benefit at 4–6 weeks. It does not cause dependence and is not habit-forming, which can be reassuring to patients wary of controlled substances.
How to Take
The medication should be taken consistently — either always with food or always without food — because food significantly affects absorption. Grapefruit juice should be avoided during treatment. If a dose is missed, the patient should take it as soon as remembered unless it is close to the next scheduled dose; doses should never be doubled.
Sources
- BuSpar (buspirone hydrochloride) prescribing information. Bristol-Myers Squibb Company. Revised November 2010. FDA Label (PDF) Primary source for all dosing, pharmacokinetics, adverse event incidence rates, drug interactions, and contraindications cited in this monograph.
- Buspirone hydrochloride tablets prescribing information. DailyMed / National Library of Medicine. DailyMed Label Current generic labeling with updated MAOI and serotonin syndrome warnings.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242. doi:10.1056/NEJMoa052963 STAR*D Level 2 switch trial; companion to the augmentation paper — provides context for sequential treatment strategies after SSRI failure.
- Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252. doi:10.1056/NEJMoa052964 STAR*D Level 2 augmentation trial directly comparing buspirone vs bupropion augmentation of citalopram; ~30% remission rate with both agents.
- Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988;45(5):444-450. doi:10.1001/archpsyc.1988.01800290060008 Long-term comparison confirming buspirone’s lack of withdrawal syndrome relative to benzodiazepines.
- Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107. doi:10.31887/DCNS.2017.19.2/bbandelow Review of pharmacotherapy for GAD positioning buspirone among first- and second-line options.
- National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline CG113. Updated 2020. NICE CG113 UK guideline addressing pharmacological options for GAD including buspirone as an alternative agent.
- Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012;1461:111-118. doi:10.1016/j.brainres.2012.04.032 Comprehensive review of buspirone’s receptor pharmacology including 5-HT1A and D2 binding profiles.
- Wilson TK, Tripp J. Buspirone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. NCBI Bookshelf Clinically oriented overview of buspirone pharmacology, dosing, and off-label uses with current references.
- Gammans RE, Westrick ML, Shea JP, Mayol RF, LaBudde JA. Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol. 1989;29(1):72-78. doi:10.1002/j.1552-4604.1989.tb03241.x Demonstrates no clinically significant age-related pharmacokinetic differences for buspirone.
- Dalhoff K, Poulsen HE, Garred P, et al. Pharmacokinetics of buspirone in patients with cirrhosis. Br J Clin Pharmacol. 1987;24(4):547-550. doi:10.1111/j.1365-2125.1987.tb03209.x Key source for the 13-fold AUC increase in hepatic impairment cited in the FDA label.
- Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1993;13(3):204-209. doi:10.1097/00004714-199306000-00009 Open-label pilot study supporting off-label use of high-dose buspirone for tardive dyskinesia.